Liquid biopsy in Hodgkin lymphoma - moving beyond the proof of principle
- PMID: 34498256
- DOI: 10.1111/bjh.17796
Liquid biopsy in Hodgkin lymphoma - moving beyond the proof of principle
Comment on
-
Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.Br J Haematol. 2021 Nov;195(4):542-551. doi: 10.1111/bjh.17719. Epub 2021 Jul 27. Br J Haematol. 2021. PMID: 34312841
References
-
- Cirillo M, Reinke S, Klapper W, Borchmann S. The translational science of hodgkin lymphoma. Br J Haematol. 2019;184(1):30-44.
-
- van Nimwegen FA, Schaapveld M, Janus CPM, Krol ADG, Petersen EJ, Raemaekers JMM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007-17.
-
- Schaapveld M, Aleman BMP, van Eggermond AM, Janus CPM, Krol ADG, van der Maazen RWM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373(26):2499-511.
-
- Borchmann S, Müller H, Haverkamp H, Baues C, Marková J, Hüttmann A, et al. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG). Leukemia. 2019;33(2):439-46.
-
- Borchmann S, Müller H, Hude I, Fuchs M, Borchmann P, Engert A. Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. Ann Oncol. 2019;30(8):1329-34.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical